Previous 10 | Next 10 |
KANSAS CITY, Kan., June 23, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmac...
KANSAS CITY, Kan., June 02, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmac...
Active Pharmaceutical Ingredient – Buspirone – One of the Most Widely Prescribed Agents in $5.5B U.S. Anxiety Market, Which Must be Taken Multiple Times Daily CTx-2103 is the Third Candidate Using Cingulate’s Proprietary Precision Timed Release™ Drug ...
KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmace...
Cingulate press release (NASDAQ:CING): Q1 GAAP EPS of -$0.44. “At its core, Cingulate has maintained a primary focus on addressing patients’ suboptimal treatment outcomes and overcoming unmet needs due to the limitations of current standard of care treatments,” ...
KANSAS CITY, Kan., May 12, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmace...
Cingulate (CING) formal corporate presentation from NobleCon18 - Noble Capital Markets 18th Annual Small & Microcap Investor Conference - April 2022. Read More >>
KANSAS CITY, Kan., April 26, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharma...
Gainers: Eiger BioPharmaceuticals (EIGR) +36%. Cyteir Therapeutics (CYT) +30%. PAVmed (PAVM) +28%. Cingulate (CING) +26%. Bone Biologics (OTCPK:BBLG) +22%. Losers: Incannex Healthcare Limited (IXHL) -12%. Jounce Therapeutics (JNCE) -9%. Rapid Micro Biosystems (RPID) -...
Cingulate press release (NASDAQ:CING): Q4 GAAP EPS of -$0.32. As of December 31, 2021, Cingulate had $16.5 million in cash and cash equivalents. Based on the Company’s current operating plan, Cingulate expects its cash and cash equivalents as of December 31, 2021 will enable the Compan...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...